MINI FUTURE OPTIONSSCHEIN PUT - VERTEX PHARMACEUTICALS | Real-time Boerse Frankfurt Warrants 02:34:14 26/06/2024 pm IST | ||
| 14.51 EUR | -0.68% |
|
| Current month | -9.09% | ||
| 1 month | -7.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 14.51 | -0.68% |
| 25/24/25 | 14.61 | +2.10% |
| 24/24/24 | 14.31 | -3.90% |
| 21/24/21 | 14.89 | +1.29% |
| 20/24/20 | 14.7 | -2.58% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 02:34 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DJ8D4V |
| ISIN | DE000DJ8D4V6 |
| Date issued | 12/01/2024 |
| Strike | 628.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 18.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.22 € |
|---|---|
| Lowest since issue | 13 € |
| Spread | 0.13 € |
| Spread % | 0.89% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
